Summary of COVID-19 MAS825 studies
Hide extended summaries
RCT 138 hospitalized COVID-19 patients with pneumonia showing no significant difference in mortality or APACHE II scores with MAS825 (anti-IL-1β/IL-18 monoclonal antibody) compared to placebo.
Jun 2023, Clinical and Experimental Immunology, https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxad065/7203697, https://c19p.org/hakim
1. Hakim et al., Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function
138 patient MAS825 late treatment RCT: 16% higher mortality (p=0.59) and 7% worse recovery (p=0.7).RCT 138 hospitalized COVID-19 patients with pneumonia showing no significant difference in mortality or APACHE II scores with MAS825 (anti-IL-1β/IL-18 monoclonal antibody) compared to placebo.
Jun 2023, Clinical and Experimental Immunology, https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxad065/7203697, https://c19p.org/hakim
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.